Grail, Inc. · NASDAQ:GRAL
Grail — Technical Presentation (October 2026)
10 slides from Grail's technical presentation, October 2026
Slide 1: Efficiency and Safety of CSO-Guided Diagnostic Workups Following MCED Testing: PATHFINDER 2
Efficiency and Safety of Cancer Signal Origin (CSO)-Guided Diagnostic Workups Following Multi-Cancer Early Detection (MCED) Testing: Results from PATHFINDER 2 (PF2) Presentation #1151RO Dax Kurbegov; Karthik V. Giridhar; Nima Nabavizadeh; Raevti Bole; Marc R. Matrana; Benjamin Rybicki; Tri Vu; Natal
Slide 2: Declaration of Interests
DECLARATION OF INTERESTS Dax Kurbegov, MD HCA Healthcare Sarah Cannon Cancer Network, Nashville, TN, USA Presenting author declarations: ● Employee of HCA Healthcare and holds stock in the company Dax Kurbegov, MD Content of this presentation is copyright and responsibility of the author. Permission
Slide 3: PATHFINDER 2 is the largest prospective, interventional MCED study in North America
PATHFINDER 2 is the largest prospective, interventional MCED a study conducted in North America to date1 Participant informed of Negative MCED test result (No cancer signal detected) Diagnostic resolutionc,d Cancer 35,878 participants Blood drawn/ Positive identified aged ≥50 years processed and MCE
Slide 4: Of 305 participants with a positive MCED test result, 290 underwent ≥1 diagnostic evaluation
Of the 305 participants with a positive MCED test result, 290 underwent ≥1 diagnostic evaluation Targeted Diagnostic Evaluationb Protocol- Diagnostic End of 12-month CSO-guided or non–CSO-guided Specified Resolution Follow-Upd dx PET-CT 156 163 With cancer With cancer at identified diagnostic resolu
Slide 5: Most evaluations were CSO-guided, most cancers identified through them, CSO predictions accurate
Most evaluations were CSO-guided, most cancers were identified through CSO-guided evaluations, and CSO predictions were accurate Targeted diagnostic evaluationsa were performed in 290 participants Cancer was identified in 167 participants 87.6% CSO-guided evaluationsb 12.4% Of these, 88.0% (147/167)
Slide 6: Diagnostic invasive procedures were more common in participants diagnosed with cancer
Diagnostic invasive procedures were more common in participants diagnosed with cancer 213 participants had an invasive procedurea • 63.8% (136/213) had a predicted CSO for which the protocol-recommended evaluation included an invasive procedure Invasive procedures were more common in participants wi
Slide 7: Diagnostic PET-CT provided limited new information; persistent MCED positivity linked to cancer diagnosis
Diagnostic PET-CT provided limited new diagnostic information; persistent MCED positivity was associated with a subsequent cancer diagnosis Targeted Diagnostic 5 diagnoses confirmed Evaluationa predicted CSO 65 participants 7 underwent dx PET-CT additional cancers after negative evaluation found 2 1
Slide 8: 95% of participants with a positive MCED test achieved diagnostic resolution
95% of participants with a positive MCED test achieved diagnostic resolution Diagnostic Resolution 163 Cancer at Median (Q1-Q3) days to diagnostic resolution1 diagnostic resolution All participants (n=290)a 48 (29-92) days 94.8% participants (275/290) had diagnostic Cancer diagnosis 37 (24-61) days
Slide 9: Conclusions
Conclusions Persistent MCED CSO-guided CSO-guided PET-CT after negative positivity on second evaluations identified evaluations were targeted evaluation blood draw may most cancers after generally focused provided limited identify participants positive MCED and safe new information who warrant test
Slide 10: Acknowledgements
Acknowledgements We acknowledge the contributions to this effort of the participants, staff, and healthcare providers who provided clinical data. Thank you!